A brolucizumab trial shows improvements in visual acuity noninferior to that of aflibercept, with risks of intraocular inflammation for some.

Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK.

( MENAFN - PR Newswire) ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX ) today announced it will participate in Chardan's 8th Annual Genetic Medicines conference on Monday ...

Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK ...

Collaboration brings together charity, university and pharmaceutical sectorsLandmark, launching today, is a three-year research partnership that aims ...

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...

One such Emirati woman is an award-winning strategic leader, Suhaila Ghubash, who's spent over 24 years transforming Dubai's ...

UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic ...

The Morris County Chamber of Commerce will host its annual Life Sciences Awards Luncheon, at the Park Avenue Club in Florham Park. The luncheon will feature keynote speaker Brent Ragans ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

Spherix Global Insights compiled data from their RealTime Dynamix™ services in Crohn’s Disease, Rheumatoid Arthritis, and Psoriasis, fielded in late April 2024 (n=104 gastroenterologists, 103 ...

For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the ...